Literature DB >> 27280961

Influences of the Big Five personality traits on the treatment response and longitudinal course of depression in patients with acute coronary syndrome: A randomised controlled trial.

Seon-Young Kim1, Robert Stewart2, Kyung-Yeol Bae3, Sung-Wan Kim3, Il-Seon Shin3, Young Joon Hong4, Youngkeun Ahn4, Myung Ho Jeong4, Jin-Sang Yoon3, Jae-Min Kim5.   

Abstract

BACKGROUND: Influences of the Big Five personality traits on the treatment response and longitudinal course of depression in patients with acute coronary syndrome: A randomised controlled trial.
METHODS: This naturalistic observational study initially recruited 1152 ACS patients; 685 patients completed personality assessments at baseline, of whom 630 were followed-up one year later. Of the 294 patients with depression, 207 participated in a 24-week double blind trial of escitalopram or placebo. The remaining 87 patients who received medical treatment only and the 391 who had not depression were also followed in a one year naturalistic observational study. The Big five personality traits were assessed using the Big Five Inventory. The influences of personality on the Hamilton Depression Rating Scale score changes were analysed using a mixed-model repeated-measures analysis of covariance.
RESULTS: A Cluster analysis identified two personality types: resilient and vulnerable. The vulnerable personality type was characterized by lower extraversion, agreeableness, and conscientiousness - but higher neuroticism - than the resilient type. This personality type was independently associated with a poorer outcome of depression in ACS patients during the 24-week treatment period and the one year longitudinal follow-up period compared to the resilient personality type, irrespective of treatment allocation. LIMITATIONS: Recruitment from a single institution may limit generalisability. Personality traits were investigated 12-weeks after ACS; thus, the responses may have been influenced by the prior receipt of escitalopram.
CONCLUSIONS: Personality types influences the treatment outcome and longitudinal course of depression in ACS patients independent of antidepressant treatment.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27280961     DOI: 10.1016/j.jad.2016.05.071

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

1.  Presence of neuroticism and antidepressant remission rates in late-life depression: results from the Neurobiology of Late-Life Depression (NBOLD) study.

Authors:  David C Steffens; Rong Wu; James J Grady; Kevin J Manning
Journal:  Int Psychogeriatr       Date:  2017-12-04       Impact factor: 3.878

2.  Anxiety and Extraversion in Lupus-Related Atherosclerosis.

Authors:  Maira Giannelou; Dimitrios Tseronis; Eleni Antypa; Clio P Mavragani
Journal:  Front Psychiatry       Date:  2018-06-19       Impact factor: 4.157

3.  Personalized repetitive transcranial magnetic stimulation temporarily alters default mode network in healthy subjects.

Authors:  Aditya Singh; Tracy Erwin-Grabner; Grant Sutcliffe; Andrea Antal; Walter Paulus; Roberto Goya-Maldonado
Journal:  Sci Rep       Date:  2019-04-04       Impact factor: 4.379

4.  Negative affectivity and social inhibition are associated with increased cardiac readmission in patients with heart failure: A preliminary observation study.

Authors:  Tin-Kwang Lin; Kai-Xun You; Chiu-Tien Hsu; Yi-Da Li; Chin-Lon Lin; Chia-Ying Weng; Malcolm Koo
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

5.  Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review.

Authors:  P B Danborg; M Valdersdorf; P C Gøtzsche
Journal:  Int J Risk Saf Med       Date:  2019

6.  Personality Profile and Clinical Correlates of Patients With Substance Use Disorder With and Without Comorbid Depression Under Treatment.

Authors:  Julia Elena Marquez-Arrico; Laura Río-Martínez; José Francisco Navarro; Gemma Prat; Ana Adan
Journal:  Front Psychiatry       Date:  2019-01-11       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.